Bharat Biotech International Ltd and Zydus Cadila have got an approval from the Drugs Controller General of India (DCGI) for human clinical trials for their indigenously developed vaccine candidates against Sars-Cov-2, the virus which causes the coronavirus disease. The drug regulator’s approval for Zydus’ ZyCoV-D comes days after Bharat Biotech got a similar nod for human trials for its vaccine candidate as the coronavirus infections continue to surge in the world’s fourth worst-hit country. The vaccine has been developed by Bharat Biotech Company in collaboration with the Indian Council of Medical Research- ICMR and the National Institute of Virology- NIV. Drug Controller General of India ‘and’ Ministry of Health and Family Welfare ‘have approved human clinical trials for Phase-1 and Phase-2 of this vaccine. The trial of this vaccine will be started on humans from next month ie from July. This vaccine is isolated from the corona virus strain through the BSL-3 (Bio-Safety Level 3) High Containment Facility of the India Biotech Company located in Hyderabad Genome Valley, which was later sent to the India Biotech Company where this indigenous vaccine Has been developed.
National Importance of Bharat Biotech
Your email address will not be published. Required fields are marked *
© Powered By Current Hunt, Designed & Developed By Quizsolver.com
This function has been disabled for Current Hunt.